Clover Health Investments Corp reported second-quarter 2026 revenue and earnings that exceeded expectations, driven by robust Medicare Advantage membership growth and a lower medical cost ratio. The company raised its full-year 2026 guidance, reflecting confidence in sustained profitability, while its Clover Assistant platform gained traction and non-insurance businesses grew rapidly. CEO Andrew Toy and CFO Ryan Schmidt highlighted disciplined cost management, improved underwriting, and a structural shift in the cost base as key drivers of the strong adjusted EBITDA performance. The company received a 3.5-star rating for the 2026 plan year and is investing to reach the 4-star threshold that would unlock bonus payments. Clover Health expects modest near-term membership growth, focusing on profitable expansion and leveraging its technology to manage medical costs, and maintains a strong balance sheet with no debt.
Clover Health Investments CorpBeat Q2 estimates and raised full-year guidance, indicating strong financial performance.
